Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut
Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value Reuters. The Danish pharmaceutical giant
